British Columbia Drug and Poison Information Centre (BC DPIC)

Millions of Americans are currently taking GLP-1 medications such as Ozempic or Wegovy for weight loss.

A major real-world study by University of California, Irvine pharmacy researchers has found serious blood-related side effects associated with antibody-drug conjugates, an increasingly important class of targeted cancer therapies.

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, PhD, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn's Abramson Cancer Center.

Southwest Research Institute evaluated NASA's medication handling practices, which currently call for removing medications from their original packaging and storing them in resealable plastic bags.

Three-quarters of people who respond well to the newest types of biologics for psoriasis can safely reduce their dosage, often even by half.

PromptSE uses structured LLM prompting to generate pharmacologically relevant side-effect representations, then feeds them into deep learning models to predict drug-side effect associations. In benchmark testing, PromptSE improved prediction performance, while PromptSE+ further boosted results by adding multi-modal drug information and graph-based refinement for sparse data.

Nine out of 10 prescriptions are filled by generic drugs - FDA-approved carbon copies of brand-name drugs with expired patents.

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the higher doses did not significantly delay disability progression, supporting the 600 mg dose as the current standard regimen with a favorable benefit-risk profile.

The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.